NCT00455936View on ClinicalTrials.gov

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

PHASE3CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

November 30, 2009

Study Completion Date

March 31, 2010

Conditions
Lung Cancer
Interventions
DRUG

Gefitinib

gefitinib 250mg tablet/ QD daily until Progression

PROCEDURE

chemotherapy

gemcitabine(1250mg/m2 iv on D1 \& 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles

Trial Locations (3)

411-769

National Cancer Center, Korea, Goyang-si

135-710

Samsung Medical Center, Seoul

138-736

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

National Cancer Center, Korea

OTHER_GOV